英临床试验：白血病靶向药新疗法显著优于化疗

Core Viewpoint - The study conducted by researchers from the University of Leeds and other institutions indicates that targeted drug combination therapy significantly outperforms traditional chemotherapy in treating chronic lymphocytic leukemia (CLL) patients, potentially changing the treatment paradigm for this common adult leukemia [1] Group 1: Study Details - The clinical trial involved 786 untreated CLL patients recruited from 96 medical centers across the UK [1] - Patients received a combination of ibrutinib and venetoclax based on individualized blood test results [1] Group 2: Efficacy Results - The five-year follow-up data shows that the progression-free survival rate for patients treated with the combination of ibrutinib and venetoclax reached 93.9%, significantly higher than other therapies [1] - The progression-free survival rate for patients using ibrutinib alone was 79%, while traditional chemotherapy had a rate of 58.1% [1] - After two years of treatment, 66.2% of patients had no detectable cancer cells in their bone marrow, compared to 48.3% in the chemotherapy group [1] Group 3: Implications - The results suggest that the combination therapy not only improves survival rates but also reduces long-term side effects, allowing patients to live without chemotherapy and enhancing their quality of life [1]